Navigation Links
Viron granted U.S. Patents for Organ Transplant and Arthritis Drug Candidates
Date:12/22/2009

's approach to drug discovery."

Viron's second therapeutic candidate, VT-346, is a powerful inhibitor of TNF-a, the therapeutic target of Enbrel(TM), Humira(TM), Cimzia(TM) and Remicade(TM), which together share a market estimated at over $20 billion annually. In head to head testing, VT-346 has proven itself to be as much as 100 times more potent than some currently marketed therapeutics, due in part to a novel mechanism of action evolved by the original virus.

The latest patent for VT-346, US 7,585,507, entitled "Nucleic acid molecules and polypeptides for immune modulation", relates to the use of VT-346 in treating immuno-modulatory disorders characterized by inflammation, such as rheumatoid arthritis, transplant rejection, asthma and inflammatory bowel disease. The protection provided by this patent also extends out to at least 2021.

Viron recently received a Notice of Allowance from the US patent office for a patent on VT-384, a protein derived from the Yatapoxvirus that targets IL-18, a cytokine expressed at sites of chronic inflammation. This cytokine has been implicated in numerous autoimmune diseases and a variety of cancers.

"IL-18 is a target of keen interest to big Pharma, with several monoclonal antibody candidates targeting IL-18 in various stages of development. Viron's discovery platform identified this natural protein that targets IL-18, which falls outside the complicated anti-IL-18 antibody patent landscape. This has hindered development of some anti-IL-18 antibody approaches. As such, we believe the commercial prospects for VT-384 in diseases such as arthritis and COPD could be very significant," said James Rae, Chief Executive Officer of Viron Therapeutics. "These issued patents also highlight our ability to discover and develop unique therapeutics which reside within pathogens and which have had millions of years to perfect strategies to modulate the immune system."

About Viron Therapeutic
'/>"/>

SOURCE Viron Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies
2. Landfill mining reduces environmental impact of growing waste
3. Landfill mining reduces environmental impact of growing waste
4. Nanowire generates power by harvesting energy from the environment
5. Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million
6. Environmental Tectonics Corporations BioMedical Division Announces New Contract
7. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
8. Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers
9. NanoLogixs Hydrogen-From-Waste Technology at Welchs Foods Featured on Environmental Radio Program
10. Nanotechs health, environmental impacts worry scientists and the public
11. Fixed C-Arms Revolutionize Operating Room Environments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... July 03, 2015 , ... Cuvettes have been used in countless labs for decades. ... find the cuvette they needed. As expected, this was a daunting and tiring process ... part because they were not able to navigate the complex catalog structure. , Now thanks ...
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech Medical SAS ... in Orthopedics, announced today the acquisition of Turner Medical, Inc ., thus ... surgical instruments to the Spine Industry. The acquisition of Turner Medical ideally supplements ...
(Date:7/1/2015)... BANGALORE, India , July 1, 2015 ... that uses next generation sequencing technology to empower cancer ... Storrer as chief executive officer. In his expanded ... responsible for all strategy, business expansion and worldwide operations ... served as Strand,s chairman and CEO since its founding ...
(Date:7/1/2015)... July 1, 2015 InferMed ... will ... evidence-based clinical s olutions suite   ... medical information products and services, announced today the acquisition of  ... support (CDS) technology company. InferMed,s Arezzo technology supports ...
Breaking Biology Technology:New Cuvette E-Commerce Website Launched by FireflySci 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4
... April 16 /PRNewswire-FirstCall/,-- Shire plc ("Shire" or the ... specialty biopharmaceutical company, announces that further to,yesterday,s announcement ... post the Circular and associated documents to its ... in the new Shire holding,company, to be called ...
... A Biogenerics Pathway that DOESN,T Keep Them Waiting, ... company CEOs flying to Capitol Hill to meet with ... (CCPM),today released a new ad urging members to keep ... legislation to create a workable approval,pathway for safe, effective ...
... 16 /PRNewswire-FirstCall/ - Victhom Human Bionics,Inc. (Victhom, TSX: ... clinical trial of its Closed-Loop neuromodulation System (CLS) ... suffering from foot drop,secondary to a central nervous ... of the trial have demonstrated that the Neurostep(TM) ...
Cached Biology Technology:New Shire Holding Company Proposal 2New Shire Holding Company Proposal 3Diverse Coalition of Purchasers Respond to BIO CEO Fly-In: There is Another Side to The Story 2Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system 2
(Date:6/11/2015)... , June 11, 2015 Daon, a ... today that its IdentityX Mobile Authentication Platform v4.0 ... Online) Alliance is an industry consortium launched in ... for simpler, stronger authentication.  In order to receive ... a rigorous series of tests that measure compliance ...
(Date:6/9/2015)... 9, 2015   MedNet Solutions , an innovative ... of clinical research, will be providing demonstrations of its ... the 2015 Drug Information Association (DIA) Annual Meeting in ... These presentations will include previews of many exciting new ... upcoming iMedNet 2015 Feature 1 Release. ...
(Date:6/8/2015)... June 8, 2015  Trovagene, Inc. (NASDAQ: TROV ), ... data featuring its Precision Cancer Monitoring SM platform will ... Biopsies conference in San Diego, CA ... Medicine Series: Integrating Clinical Genomics and Cancer Therapy in ... 13-16. "We continue to advance our clinical ...
Breaking Biology News(10 mins):Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 2Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 4
... Acute lung injury caused by cell death, high and ... excess fluid in the lungs (pulmonary edema), may be ... researchers at Yale School of Medicine report in the ... study, which was completed in the laboratory of senior ...
... A first-of-its kind analysis of fifty years of remotely sensed ... in the size and number of more than 10,000 ponds ... and published this week in the Journal of Geophysical Research, ... with recent climate warming in Alaska and may have profound ...
... agent completely prevented the development of bone tumors in ... study, providing early evidence that it could treat, or ... for a number of cancers when they start to ... D. Anderson Cancer Center reported in the journal Cancer ...
Cached Biology News:Key to acute lung injury lies in Ang2 protein 2Shrinking ponds signal warmer, dryer Alaska 2'Trojan Horse' agent halts bone metastasis in mice 2'Trojan Horse' agent halts bone metastasis in mice 3
Agar, 500 g. Noble Agar.Moisture: < 10%, ash: < 1.6%, EEO (-mr): < 0.450 (pH 8.4). Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Ms anti-Cyclophilin D...
... Intended to qualitatively ... in formalin-fixed, paraffin-embedded (FFPE) ... spreads, and cell preparations, ... Hybridization (CISH). Fluorescent In ...
Mouse GM CSF Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
Biology Products: